Targeted Quantitative Plasma Metabolomics Identifies Metabolite Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection Fraction

Fawaz Naeem,Teresa C Leone,Christopher Petucci,Clarissa Shoffler,Ravindra Kodihalli,Tiffany Hidalgo,Cheryl Tow-Keogh,Jessica Y Mancuso,Iphigenia Tzameli,Donald Bennett,John D Groarke,Rachel J. Roth Flach,Daniel J Rader,Daniel P Kelly

DOI: https://doi.org/10.1101/2024.07.24.24310961

2024-07-25

Abstract:Background. Two general phenotypes of heart failure (HF) are recognized: HF with reduced ejection fraction (HFrEF) and with preserved EF (HFpEF). To develop HF disease phenotype-specific approaches to define and guide treatment, distinguishing biomarkers are needed. The goal of this study was to utilize quantitative metabolomics on a large, diverse population to replicate and extend existing knowledge of the plasma metabolic signatures in human HF. Methods. Quantitative, targeted LC/MS plasma metabolomics was conducted on 787 samples collected by the Penn Medicine BioBank from subjects with HFrEF (n=219), HFpEF (n=357), and matched non-failing Controls (n=211). A total of 90 metabolites were analyzed, comprising 28 amino acids, 8 organic acids, and 54 acylcarnitines. 733 of these samples were also processed via an OLINK protein panel for proteomic profiling. Results. Consistent with previous studies, unsaturated forms of medium/long chain acylcarnitines were elevated in the HFrEF group to a greater extent than the HFpEF group compared to Controls. A number of amino acid derivatives, including 1- and 3-methylhistidine, homocitrulline, and symmetric (SDMA) and asymmetric (ADMA) dimethylarginine were elevated in HF, with ADMA elevated uniquely in HFpEF. Plasma branched-chain amino acids (BCAA) were not different across the groups; however, short-chain acylcarnitine species indicative of BCAA catabolism were significantly elevated in both HF groups. The ketone body 3-hydroxybutyrate (3-HBA) and its metabolite C4-OH carnitine were uniquely elevated in the HFrEF group. Linear regression models demonstrated a significant correlation between plasma 3-HBA and NT-proBNP in both forms of HF, stronger in HFrEF. Conclusions. These results identify plasma signatures that are shared as well as potentially distinguish between HFrEF and HFpEF. Metabolite markers for ketogenic metabolic re-programming in extra-cardiac tissues were identified as unique signatures in the HFrEF group, possibly related to the lipolytic action of increased levels of BNP. Future studies will be necessary to further validate these metabolites as HF biosignatures that may guide phenotype-specific therapeutics and provide insight into the systemic metabolic responses to HFpEF and HFrEF.

Cardiovascular Medicine

What problem does this paper attempt to address?

### Problems the Paper Aims to Solve

This paper aims to identify metabolic markers that distinguish heart failure with reduced ejection fraction (HFrEF) from heart failure with preserved ejection fraction (HFpEF) through large-scale, diverse cohort studies using quantitative plasma metabolomics methods. Specifically, the research objectives include:

1. **Validation and Expansion of Existing Knowledge**: Validate and expand existing knowledge about the plasma metabolic characteristics of human heart failure by analyzing a large number of samples.
2. **Identification of Distinguishing Markers**: Identify specific metabolic markers that can distinguish HFrEF from HFpEF, which may aid in the development of future treatment strategies tailored to different heart failure phenotypes.
3. **Exploration of Metabolic Reprogramming**: Investigate whether there is specific metabolic reprogramming in heart failure patients, particularly changes in ketone body metabolism in non-cardiac tissues.

### Research Background

Heart failure (HF) is a common cardiovascular disease that can be divided into two main types based on ejection fraction:
- **HFrEF**: Heart failure with reduced ejection fraction.
- **HFpEF**: Heart failure with preserved ejection fraction.

Despite recent advances in the treatment of heart failure, current treatment regimens are often not tailored to specific phenotypes. Therefore, identifying biomarkers that can distinguish different heart failure phenotypes is an important unmet need, which will help in developing treatments targeted at specific phenotypes.

### Research Methods

Researchers collected 787 samples from the University of Pennsylvania Medical Biobank, including:
- HFrEF patients (n=219)
- HFpEF patients (n=357)
- Non-heart failure control group (n=211)

These samples underwent quantitative targeted liquid chromatography/mass spectrometry (LC/MS) plasma metabolomics analysis, analyzing a total of 90 metabolites, including 28 amino acids, 8 organic acids, and 54 acylcarnitines. Additionally, 733 samples were analyzed using Olink proteomics technology for proteomic analysis.

### Main Findings

1. **Acylcarnitine Levels**: Compared to the control group, levels of unsaturated medium-chain and long-chain acylcarnitines were significantly elevated in the HFrEF group, with fewer changes in the HFpEF group.
2. **Amino Acid Derivatives**: Various amino acid derivatives, including 1-methylhistidine, 3-methylhistidine, homocitrulline, and symmetric and asymmetric dimethylarginine, were elevated in heart failure patients, with asymmetric dimethylarginine (ADMA) specifically elevated in the HFpEF group.
3. **Branched-Chain Amino Acids (BCAA) and Their Metabolites**: BCAA levels did not differ significantly between groups, but short-chain acylcarnitines derived from BCAA degradation were significantly elevated in both HFrEF and HFpEF groups.
4. **Ketone Body Metabolism**: 3-hydroxybutyric acid (3-HBA) and its metabolite C4-OH carnitine were specifically elevated in the HFrEF group and positively correlated with plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, suggesting a potential mechanism involving the heart-fat-liver axis.

### Conclusion

This study identified shared and specific plasma metabolic markers in HFrEF and HFpEF, particularly the unique changes in ketone body metabolism in HFrEF, which may be related to BNP-mediated lipolysis during heart failure. These findings provide a basis for further validation of these metabolic markers as biomarkers for heart failure and may guide treatment strategies tailored to specific heart failure phenotypes.